Regeneron Pharmaceuticals (REGN): financials, SEC filings and peers

Regeneron Pharmaceuticals (REGN) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Tarrytown, New York.

It was founded in 1988 and joined the S&P 500 on May 1, 2013.

Its fiscal year ends in December, and its shares trade on the Nasdaq.

In its SEC filings it is classified as “Pharmaceutical Preparations”.

Regeneron Pharmaceuticals at a glance

Revenue (12 months): $16.9B
Revenue growth: +18.6%
Operating margin: 28.8%
Net income (12 months): $4.8B
Free cash flow (12 months): $3.8B
Cash: $3.7B
Debt: $2.0B
Diluted EPS (12 months): $45.30

Twelve months to September 30, 2026, from the 10-Q filed October 30, 2026.

Latest twelve months

Over the twelve months to September 30, 2026, Regeneron Pharmaceuticals reported revenue of $16.9 billion, up 18.6% from a year earlier.

Its operating margin was 28.8%, up 2.9 percentage points from a year earlier: for every $100 of sales, about $29 was left as operating profit.

Net income was $4.8 billion (28.5% of revenue), 5.2% higher than a year earlier.

Operating cash flow was $4.8 billion and capital spending $1.0 billion, leaving free cash flow of $3.8 billion (22.6% of revenue).

At the end of the period it held $3.7 billion in cash and $2.0 billion in debt, a net cash position of $1.7 billion.

The diluted share count fell 1.5% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $8.5 billion in fiscal 2020 to $14.3 billion in fiscal 2025, about 11.0% a year.
Revenue has grown for 3 fiscal years in a row.
Operating margin narrowed from 42.1% to 24.9% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$16.1B	$12.2B	$13.1B	$14.2B	$14.3B
Revenue growth	89.1%	-24.3%	7.8%	8.3%	1.0%
Operating margin	55.7%	38.9%	30.9%	28.1%	24.9%
Net income	$8.1B	$4.3B	$4.0B	$4.4B	$4.5B
Free cash flow	$6.5B	$4.4B	$3.9B	$3.7B	$4.1B
Diluted EPS	$71.97	$38.22	$34.77	$38.34	$41.48

Fiscal years as reported in Regeneron Pharmaceuticals’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed October 30, 2026 — quarterly report
8-K filed October 30, 2026 — Earnings results
8-K filed October 6, 2026 — Material agreement; Earnings results
8-K filed September 30, 2026 — Executive or director change
10-Q filed July 30, 2026 — quarterly report
8-K filed July 30, 2026 — Earnings results
8-K filed July 6, 2026 — Earnings results
8-K filed June 17, 2026 — Shareholder vote results

All Regeneron Pharmaceuticals filings on SEC EDGAR

Companies like Regeneron Pharmaceuticals

Other S&P 500 companies in Biotechnology:

More from Health Care

All 60 Health Care companies →

Questions about Regeneron Pharmaceuticals

Is Regeneron Pharmaceuticals's revenue growing?

Yes. Revenue for the twelve months to September 30, 2026 was $16.9 billion, up 18.6% from a year earlier, according to its SEC filings.

Is Regeneron Pharmaceuticals profitable?

Yes. It earned $4.8 billion in net income over the twelve months to September 30, 2026, a net margin of 28.5%.

Does Regeneron Pharmaceuticals have more cash or more debt?

At September 30, 2026 it had $3.7 billion in cash and $2.0 billion in debt, so more cash than debt.

When did Regeneron Pharmaceuticals last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on October 30, 2026.

Which companies are similar to Regeneron Pharmaceuticals?

In the S&P 500, Regeneron Pharmaceuticals is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Amgen (AMGN), Biogen (BIIB), Gilead Sciences (GILD), Incyte (INCY) are in the same group.

Understand the numbers

Source: Regeneron Pharmaceuticals’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.